Restore Delivered sells a combined experience: medication at home, clinical guidance online and wellness services in a Restore studio. That combination creates several separate evidence questions. What exactly is prescribed? Who provides the care? Which studio benefits are actually accessible? And do published weight-loss studies establish results for this particular program? The consulted public documentation supports a description of Restore’s service model, but it does not bridge every gap between a recognizable drug ingredient, a compounded preparation and a measured patient outcome.
This review examines Restore GLP-1 through those distinctions rather than treating its marketing as a clinical performance report. The official pages, consulted October 19, 2026, advertise compounded semaglutide and tirzepatide, starting prices tied to a 12-month plan, and both home and studio pathways. They also disclose that prescriptions are not guaranteed. Our approach follows the distinction explained in what public provider documents can prove: documentation can establish what a business promises without independently verifying its clinical results, pharmacy practices or service reliability.
At a glance
- Advertised medication prices
- Compounded semaglutide starts at $99 per month and compounded tirzepatide at $145 per month with the 12-month Transformation Stack; these are not confirmed standalone month-to-month prices.Sources: [5]
- Compounded products
- Restore states that its compounded medications are not FDA approved and have not undergone FDA review for safety, effectiveness or quality.
- Review follows checkout
- Patients complete medical intake after checkout. A licensed clinician reviews the information, may request more, and does not guarantee a prescription.
- Studio geography
- Although Restore advertises more than 200 locations, its FAQ specifically places the included wellness services at Restore Alexandria.Sources: [5]
Start with the product, not the ingredient’s reputation
Restore identifies its medication options as compounded semaglutide and compounded tirzepatide. It describes tirzepatide as dual-action GLP-1/GIP and says the preparations contain the same active ingredients as named FDA-approved products. That comparison is a provider statement, not evidence that the dispensed preparation has the approval or supporting evidence of a branded medicine. Restore itself expressly acknowledges that the compounded products are not FDA approved and have not been reviewed by that agency for safety, effectiveness or quality.
FDA’s guidance supplies the relevant boundary: compounded preparations do not undergo FDA premarket review, and FDA recommends them when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence or settle whether a particular provider offers appropriate care. The useful question is why a particular preparation meets an individual need—not whether the business uses a familiar ingredient name.
The public documentation leaves important product details unresolved, including the GLP-1 route, presentation, additional ingredients and supply period per shipment. A statement that medication can be shipped home or administered in a studio does not establish those details. Before comparing Restore with another offer, request the actual prescribed product description and pharmacy label information. Our guide to approved medicines and compounded preparations explains why product identity and regulatory status are separate evidence questions.
| Documented statement | Supported interpretation | Question still to resolve |
|---|---|---|
| Compounded semaglutide and tirzepatide | The program advertises compounded preparations | What exact formulation, route and presentation will be prescribed? |
| From $99 or $145 per month | Starting prices reference the 12-month plan | What is collected initially, and when are later charges due? |
| Plan review within 24 hours | A clinical-review target is advertised | When will medication arrive after approval? |
| More than 200 Restore locations | Restore describes a broad studio network | Can the included benefits be used anywhere besides Alexandria? |
| Clinical team through the member portal | A follow-up contact channel exists | What response times and visits are included? |
Clinical studies are not Restore outcome reports
Restore’s marketing references weight-loss research, but the consulted documentation does not demonstrate that those results were measured among Restore patients. That distinction matters because a clinical trial studies a defined intervention, population and follow-up process. A provider’s service package adds other variables: the prescribed preparation, pharmacy fulfillment, communication and ongoing care. Evidence supporting an ingredient in a specific studied product cannot simply be relabeled as evidence that this whole package produces the same outcomes.
For example, STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes, over 68 weeks, with lifestyle intervention in both groups. SURMOUNT-1 studied subcutaneous tirzepatide in adults with obesity or overweight plus a weight-related complication, excluding diabetes, over 72 weeks. Gastrointestinal tolerability and treatment discontinuation were part of those studies. Novo Nordisk funded STEP 1; Eli Lilly funded SURMOUNT-1. Neither was a trial of Restore’s program or compounded preparations.
Those studies therefore provide clinical context, not a Restore performance estimate or a head-to-head ranking between its options. They do not predict an individual’s response, validate unspecified formulations or prove that bundled studio services improve medication outcomes. Readers weighing advertised percentages should first ask whose patients were measured and what product they received. The distinction is developed further in why a clinical trial is not a company performance report.
Checkout comes before clinical approval
Restore’s stated sequence is commercially important: checkout comes first, followed by the online medical intake. A licensed clinician reviews the answers and may request additional information before approving treatment. The privacy policy says intake information can include height, weight, medical history and current medications. The medication choice is not presented as a guaranteed customer selection; Restore says a clinician considers history, goals and medications to determine which option may be appropriate.
A separate page advertises review and development of a tailored plan within 24 hours. That is a clinical-review claim, not a promised prescription, shipping deadline or support-response standard. The terms explicitly say there is no guarantee of treatment or a prescription. Because the public documents do not explain what refund follows a denied prescription, the financial consequences of an unsuccessful review should be clarified before checkout rather than assumed from the review timeline.
The website and services are intended for adults 18 and older and for United States residents. Those statements do not establish eligibility in every state. The consulted documents do not provide a state-by-state telemedicine or shipping list, complete medical exclusions, required laboratory testing or provider-specific BMI criteria. NIDDK emphasizes discussing health conditions, other medicines, side effects and costs with a clinician; a public review cannot substitute for that individual assessment.
Read the starting prices alongside the selected term
Restore advertises compounded semaglutide from $99 per month and compounded tirzepatide from $145 per month with the 12-month Transformation Stack. Both the starting-at language and the 12-month condition matter. The pages also offer month-to-month, three-month and six-month plans, but the consulted documentation does not establish their complete medication prices. Nor does the monthly presentation establish whether the longer plan is collected upfront, billed in installments or handled through another payment schedule.
Restore says medication, studio care and clinical guidance are included in one plan, and advertises that the price stays locked as the dose increases. These are commercial promises rather than independent findings about value. The public documents do not fully explain initial collection, renewal mechanics or how the advertised dose-related price statement interacts with every plan choice. The terms also say that if a listed price is incorrect, customers may accept the corrected price or forgo the transaction.
Cancellation requires equally careful reading. The cancel-anytime language applies to month-to-month plans, while the FAQ ties commitment to the one-, three-, six- or 12-month term selected at checkout. It does not establish equivalent exit rights for longer plans, refund eligibility or notice deadlines. Separately, the service is not insurance, and its terms require customers not to submit claims for the telemedicine services to Medicare or other federal, state or private payers.
The studio bundle has a specific geographic qualification
The studio component distinguishes Restore from a medication-only offer. Its full 12-month plan lists 12 InBody scans, one Lipo-B12 intramuscular administration, two infrared sauna sessions, two red light therapy sessions and two GLP-1 Support IVs. These are totals across the full plan, not monthly allowances. Restore assigns the included studio services a value of up to $1,210; that is its commercial valuation, not an independently established benefit or savings calculation.
Shorter plans advertise smaller in-person care allowances: $713 for six months, $333 for three months and $177 for one month. The process directs customers to book a studio session to use included credits. However, the FAQ specifically says included wellness services are provided at Restore Alexandria. That narrower statement should guide expectations unless Restore confirms otherwise; the broader promotion of more than 200 locations does not establish that every studio accepts these benefits.
The home pathway advertises online treatment with a board-certified provider, home delivery and studio benefits. The studio pathway adds in-person dosing support and accountability from a local nurse, with the option to add studio visits after starting online. Yet the terms classify local nursing and studio services as education, accountability and wellness—not medical clearance. The consulted evidence does not establish that the wellness bundle improves weight-loss outcomes or replaces the prescribing clinician’s evaluation.
Pharmacy fulfillment is described, but not fully identified
Restore states that it does not manufacture medications and that medications ship from a licensed pharmacy. It also describes the compounded preparations as prescribed and prepared for individual patients by a licensed compounding pharmacy. These statements explain the claimed division of responsibilities without identifying the dispensing pharmacy by name. The consulted documents likewise do not name the contracted clinical entity or establish which clinician would treat a particular customer.
The terms permit customers to direct a prescription to a pharmacy of their choosing, despite Restore’s use of preferred pharmacies. The practical condition is to email support@restoredelivered.com before completing the order. That is a meaningful option, but the documentation does not explain its effect on medication charges, package benefits or fulfillment timing. Customers considering another pharmacy should resolve those operational and payment questions before ordering, rather than assuming the bundled arrangement remains unchanged.
Fast shipping is advertised as included if a prescription is granted, without a specified arrival deadline, carrier, cold-chain procedure or replacement policy. Restore also warns that actual appearance and labeling may differ from website images. For an injectable GLP-1 delivery that arrives warm or inadequately refrigerated, FDA explicitly recommends not using it and contacting the provider or dispensing pharmacy. That guidance is important given the limited published delivery detail; it is not evidence that Restore has had such a shipping problem.
Follow-up needs more detail than a portal address
Restore provides a documented clinical contact path: the member portal. Its FAQ directs patients there for guidance and advises immediate medical care for severe symptoms. What remains unclear is the routine service level—scheduled follow-up frequency, included visits, portal response times and support hours. Those details affect how the advertised clinical guidance functions after the first prescription, particularly when a patient needs an assessment rather than simply a shipment update.
NIDDK describes follow-up as attention to tolerance and response, not merely continuation of payments. FDA has also reported errors in measuring or administering compounded medication, including some associated with hospitalization. Those reports do not establish a Restore-specific event rate or prove causation in an individual case. They do support asking who supplies understandable product-specific instructions and whom to contact for clarification, rather than attempting to derive administration instructions from marketing or a review.
Restore names Dr. Henry Legere as its chief medical officer and credits him with helping shape protocols and offerings. It also advertises more than 1,000 local nurses and LegitScript certification. These are attributed website claims, not credentials independently verified here, and they do not identify a patient’s prescriber. Before enrollment, ask how the prescribing team, pharmacy and local nurse communicate. Our guide to clinical follow-up beyond renewal notices outlines why that division of responsibility matters.
Privacy and accountability extend across several parties
The terms attribute the website and services to Restore Hyper Wellness, its owners and affiliates, and contracted third parties. The privacy policy says Restore does not sell health information, while permitting disclosure to participating providers, pharmacies, studios and clinical staff supporting the program. Information shared during clinical care is also governed by the treating provider’s own privacy notice. Consequently, the website policy alone is not the complete account of how a patient’s clinical information is handled.
Customers may request review, correction or deletion of information, subject to legal and clinical recordkeeping requirements. The terms caution that email and text are not fully secure. For administrative assistance, the published support address is support@restoredelivered.com; the terms also list Restore Hyper Wellness at 13740 North Highway 183, L2, Austin, Texas 78750-1835. Those contact paths help distinguish order questions from clinical questions directed through the member portal.
The terms include binding individual arbitration, a small-claims exception, and waivers of jury trial and class or representative actions. This review does not assess their legal effect. Their presence nevertheless makes reviewing the actual terms before purchase worthwhile, alongside obtaining written answers about denied prescriptions, longer-plan cancellation, studio eligibility and dispensing responsibilities. Clear documentation across those subjects would make the program easier to evaluate than broad assurances about convenience or a large network alone.
Questions & answers
Can I buy Restore’s $99 semaglutide offer month to month?
The $99-per-month starting price is expressly associated with the 12-month Transformation Stack, not a confirmed standalone monthly plan. The same qualification applies to tirzepatide’s $145 starting price. Restore offers month-to-month plans, but the consulted documents do not give their complete prices or confirm the longer plan’s collection schedule.
Does paying at checkout guarantee a prescription?
No. Medical intake follows checkout, and a licensed clinician may request further information before deciding whether treatment is appropriate. The terms explicitly do not guarantee care or a prescription. The public documentation does not explain the refund outcome if treatment is denied, so obtain that answer before paying.
Can I use the included wellness services at any Restore location?
That is not established. Restore promotes more than 200 locations, but its FAQ specifically places included wellness services at Restore Alexandria. Ask for confirmation of the eligible location and booking conditions before assigning value to the bundle. The documents do not clarify credit expiration or substitutions.
Does Restore identify the pharmacy, and can I choose another one?
The consulted documents describe licensed pharmacy fulfillment without naming the dispensing pharmacy. The terms allow another pharmacy but require emailing support@restoredelivered.com before completing the order. They do not clarify resulting costs or changes to fulfillment, so request those details before choosing that route.
Does the 24-hour claim mean medication arrives the next day?
No. The advertised 24-hour period concerns reviewing answers and building a tailored plan. Shipping is described separately as fast and included if a prescription is granted, with no specific arrival commitment. The documents do not establish carrier, transit duration or replacement arrangements for a lost or damaged shipment.
Who helps with clinical questions after enrollment?
Restore directs patients to the clinical care team through the member portal and advises immediate medical care for severe symptoms. Local nurses provide education, accountability and wellness support, not medical clearance. Ask how often clinical follow-up occurs and how quickly portal messages receive a response; the public documents do not specify those standards.
Our assessment
Restore documents a recognizable combined offering: compounded medication, online prescribing review, pharmacy delivery and a defined studio-services bundle. Its disclosures about compounded status, prescription uncertainty and the limited role of local nursing are useful. However, public documentation does not establish Restore-specific clinical outcomes, identify the dispensing pharmacy, or resolve essential formulation, billing, refund and follow-up details. The Alexandria restriction also materially qualifies the apparent reach of its studio benefits. A reasonable documentary assessment is therefore neither a clinical endorsement nor a dismissal: the basic service is described, but its evidence and operational transparency remain incomplete. Before committing—especially to the 12-month plan behind the lowest advertised prices—obtain written product details, payment and denial terms, eligible studio locations and a clear account of ongoing clinical responsibility.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Restore GLP-1 / Restore Delivered — Restore Hyper Wellness — official website ↗
- Restore GLP-1 / Restore Delivered — Restore Hyper Wellness — terms ↗
- Restore GLP-1 / Restore Delivered — Restore Hyper Wellness — how it works ↗
- Restore GLP-1 / Restore Delivered — Restore Hyper Wellness — privacy ↗